Good response.
I attended last night a teleconference, live from New York, to 15 Cities in the US, with some of the best HIV experts (M. Fischel, J. Mellors, C. Benson and others) giving an update of the Geneva conference. The state of the art antiretroviral therapy continues to be HAART with PI's, Sustiva and Abacavir are yet to be released, and although they look promissing, there is not enough data yet.
PI therapy, with all its shortcomings continues to be the Standard of Care in the US (and most of the Western World). What we will have in the future is "More Choices." Viracept is the best PI on the market, and it will be so for a long time. It also works well with the new agents, works very well with other PI's and NNRTI's, and is the best on BID dosing.
For some reason, AGPH has, and continues, been clobbered over this past year, inspite of excellent news and returns. A company that is making a lot of money, and is using is gains to grow.
I will stay very long, sooner or later it will come up. You can not argue with quality.
JLL
PS. I do not even want the 30 days free at "The Street"
I am going to work and see real patients, Bye |
